STUDY ON PHARMACOKINETICS AND RELATIVE BIOAVAILABILITY OFDOMESTIC CONTROLLED-RELEASE THEOPHYLLINE TABLETAFTER SINGLE AND MULTIPLE DOES ORAL
Mo Hong
Abstract
Mo Hong
Abstract
HPLC method was used to study the pharmacokinetics and relative bioavailability ofdomestic controlled - release theophylline tablet (DCRTT) and imported controlled - release theophylline capsule (theovent) in 11 healthy volunteers, Our result indicated that the pharmacokinetic parameters for DCRTTwere: T1/2Ke= 14. 07 ± 1.32 h, T1/2Ka= 1.26 ± 0.14 h, V / F(c) =46.2 ± 9.25 1, Cmax = 4. 21 ± 0. 53 mg/l, AUC = 108.6±17. 97 mg· h· 1-1, Relative bioavailability was 0. 844 compared with theovent and the execretion rate of parent drug in urine was 9. 7% within 24 h; for the theovent were: T1/2Ke=9. 89 ± 0.62h, T1/2Ka= 0.52±0.08 h, V / F(c) =27.8± 6.71, Cmax = 7.64±1.21 mg/l, AUC = 128.7 ±25.80 mg · h-1·L-1.The steady - state pharmacokinetics of DCRTT and theovent were investigated in 9 asthma or COPD patients. The result showed that flutuation rate of DCRTT in range of effecting concentration was smaller than that of theovent(P0. 5) .
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
HPLC method was used to study the pharmacokinetics and relative bioavailability ofdomestic controlled - release theophylline tablet (DCRTT) and imported controlled - release theophylline capsule (theovent) in 11 healthy volunteers, Our result indicated that the pharmacokinetic parameters for DCRTTwere: T1/2Ke= 14. 07 ± 1.32 h, T1/2Ka= 1.26 ± 0.14 h, V / F(c) =46.2 ± 9.25 1, Cmax = 4. 21 ± 0. 53 mg/l, AUC = 108.6±17. 97 mg· h· 1-1, Relative bioavailability was 0. 844 compared with theovent and the execretion rate of parent drug in urine was 9. 7% within 24 h; for the theovent were: T1/2Ke=9. 89 ± 0.62h, T1/2Ka= 0.52±0.08 h, V / F(c) =27.8± 6.71, Cmax = 7.64±1.21 mg/l, AUC = 128.7 ±25.80 mg · h-1·L-1.The steady - state pharmacokinetics of DCRTT and theovent were investigated in 9 asthma or COPD patients. The result showed that flutuation rate of DCRTT in range of effecting concentration was smaller than that of theovent(P0. 5) .
Key concepts: Theophylline, Bioavailability, Pharmacokinetics, Cmax, Pharmacology, Bronchodilator, Capsule, Chemistry